The Cooper Companies, Inc. (COO) 10-Q 30 Aug 19 2019 Q3 Quarterly report Financial data

Cover Page

Cover Page - shares	9 Months Ended
	Jul. 31, 2019	Aug. 23, 2019
Cover page.
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jul. 31, 2019
Document Transition Report	false
Entity File Number	1-8597
Entity Registrant Name	The Cooper Companies, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-2657368
Entity Address, Address Line One	6140 Stoneridge Mall Road
Entity Address, Address Line Two	Suite 590
Entity Address, City or Town	Pleasanton
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94588
City Area Code	925
Local Phone Number	460-3600
Title of 12(b) Security	Common Stock, $.10 par value
Trading Symbol	COO
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		49,573,612
Entity Central Index Key	0000711404
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--10-31
Amendment Flag	false

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Jul. 31, 2019	Jul. 31, 2018	Jul. 31, 2019	Jul. 31, 2018
Income Statement [Abstract]
Net sales (Note 2)	$ 679.4	$ 660	$ 1,961.8	$ 1,881.3
Cost of sales	228.7	233.2	660	679.1
Gross profit	450.7	426.8	1,301.8	1,202.2
Selling, general and administrative expense	249.8	251	746.6	724.7
Research and development expense	21.5	22.5	63.4	62.2
Amortization of intangibles	37.2	37.7	110.7	110.5
Impairment of intangibles	0	0	0	24.4
Gain on sale of an intangible (Note 5)	0	0	(19)	0
Operating income	142.2	115.6	400.1	280.4
Interest expense	16.7	22.8	53.3	59.9
Other (income) expense, net	(1.5)	2.4	(2.1)	1.3
Income before income taxes	127	90.4	348.9	219.2
Provision (benefit) for income taxes (Note 7)	6.9	(10.4)	3.2	180
Net income	$ 120.1	$ 100.8	$ 345.7	$ 39.2
Earnings per share - basic (in dollars per share) (Note 8)	$ 2.43	$ 2.05	$ 7	$ 0.80
Earnings per share - diluted (in dollars per share) (Note 8)	$ 2.40	$ 2.03	$ 6.91	$ 0.79
Number of shares used to compute earnings per share:
Basic (in shares)	49.5	49.1	49.4	49
Diluted (in shares)	50.1	49.7	50	49.6

Consolidated Condensed Balance

Consolidated Condensed Balance Sheets - USD ($) $ in Millions	Jul. 31, 2019	Oct. 31, 2018
Current assets:
Cash and cash equivalents	$ 112.7	$ 77.7
Trade accounts receivable, net of allowance for doubtful accounts of $17.1 at July 31, 2019 and $19.0 at October 31, 2018	404.7	374.7
Inventories (Note 4)	502.1	468.8
Prepaid expense and other current assets	131.3	169.7
Total current assets	1,150.8	1,090.9
Property, plant and equipment, at cost	2,086.9	1,930.3
Less: accumulated depreciation and amortization	1,021.5	954.3
Property, plant and equipment, net	1,065.4	976
Goodwill (Note 5)	2,391.4	2,392.1
Other intangibles, net (Note 5)	1,438.6	1,521.3
Deferred tax assets	63.1	58.4
Other assets	63.5	74.1
Total assets	6,172.8	6,112.8
Current liabilities:
Short-term debt (Note 6)	390	37.1
Accounts payable	141.5	146.4
Employee compensation and benefits	89.5	94
Other current liabilities	268.4	259
Total current liabilities	889.4	536.5
Long-term debt (Note 6)	1,422.6	1,985.7
Deferred tax liabilities	31.5	31
Long-term tax payable	124.8	141.5
Accrued pension liability and other	89	110.3
Total liabilities	2,557.3	2,805
Contingencies (see Note 13)
Stockholders’ equity:
Preferred stock, 10 cents par value, shares authorized: 1.0; zero shares issued or outstanding	0	0
Common stock, 10 cents par value, shares authorized: 120.0; issued 53.2 at July 31, 2019 and 52.8 at October 31, 2018	5.3	5.3
Additional paid-in capital	1,607.6	1,572.1
Accumulated other comprehensive loss	(481.8)	(430.7)
Retained earnings	2,905.4	2,576
Treasury stock at cost: 3.6 shares at July 31, 2019 and 3.6 shares at October 31, 2018	(421.2)	(415.1)
Noncontrolling interests	0.2	0.2
Stockholders’ equity (Note 10)	3,615.5	3,307.8
Total liabilities and stockholders' equity	$ 6,172.8	$ 6,112.8

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jul. 31, 2019	Jul. 31, 2018	Jul. 31, 2019	Jul. 31, 2018
Statement of Comprehensive Income [Abstract]
Net income	$ 120.1	$ 100.8	$ 345.7	$ 39.2
Other comprehensive loss:
Foreign currency translation adjustment, net of tax	(65.2)	(69.6)	(51.1)	(10.3)
Comprehensive income	$ 54.9	$ 31.2	$ 294.6	$ 28.9

Consolidated Condensed Balanc_2

Consolidated Condensed Balance Sheets (Parenthetical) - USD ($) $ in Millions	Jul. 31, 2019	Oct. 31, 2018
Statement of Financial Position [Abstract]
Trade accounts receivable, allowance for doubtful accounts	$ 17.1	$ 19
Preferred stock, par value (in dollars per share)	$ 0.1	$ 0.1
Preferred stock, authorized (in shares)	1,000,000	1,000,000
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.1	$ 0.1
Common stock, authorized (in shares)	120,000,000	120,000,000
Common stock, issued (in shares)	53,200,000	52,800,000
Treasury stock (in shares)	3,600,000	3,600,000

Consolidated Condensed Statemen

Consolidated Condensed Statements of Stockholders' Equity - USD ($) shares in Millions, $ in Millions	Total	Common Shares	Treasury Stock	Treasury Stock Par Net Value	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings	Noncontrolling Interests
Beginning balance (in shares) at Oct. 31, 2017		48.8	3.6
Beginning balance at Oct. 31, 2017	$ 3,175.8	$ 4.9	$ (415.1)	$ 0.3	$ 1,526.7	$ (375.3)	$ 2,434.2	$ 0.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	(122.5)						(122.5)
Other comprehensive income (loss), net of tax	102.3					102.3
Issuance of common stock for stock plans, net (in shares)		0.2
Issuance of common stock for stock plans, net	(10.5)	$ 0.1			(10.6)
Dividends on common stock	(1.4)						(1.4)
Share-based compensation expense	12.7				12.7
Ending balance (in shares) at Jan. 31, 2018		49	3.6
Ending balance at Jan. 31, 2018	3,156.4	$ 5	$ (415.1)	0.3	1,528.8	(273)	2,310.3	0.1
Beginning balance (in shares) at Oct. 31, 2017		48.8	3.6
Beginning balance at Oct. 31, 2017	3,175.8	$ 4.9	$ (415.1)	0.3	1,526.7	(375.3)	2,434.2	0.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	39.2
Ending balance (in shares) at Jul. 31, 2018		49.1	3.6
Ending balance at Jul. 31, 2018	3,226.6	$ 5	$ (415.1)	0.3	1,551.4	(385.6)	2,470.5	0.1
Beginning balance (in shares) at Jan. 31, 2018		49	3.6
Beginning balance at Jan. 31, 2018	3,156.4	$ 5	$ (415.1)	0.3	1,528.8	(273)	2,310.3	0.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	60.9						60.9
Other comprehensive income (loss), net of tax	(43)					(43)
Issuance of common stock for stock plans, net (in shares)		0.1
Issuance of common stock for stock plans, net	0.1				0.1
Share-based compensation expense	13.6				13.6
Ending balance (in shares) at Apr. 30, 2018		49.1	3.6
Ending balance at Apr. 30, 2018	3,188	$ 5	$ (415.1)	0.3	1,542.5	(316)	2,371.2	0.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	100.8						100.8
Other comprehensive income (loss), net of tax	(69.6)					(69.6)
Issuance of common stock for stock plans, net	0.8				0.8
Dividends on common stock	(1.5)						(1.5)
Share-based compensation expense	8.1				8.1
Ending balance (in shares) at Jul. 31, 2018		49.1	3.6
Ending balance at Jul. 31, 2018	3,226.6	$ 5	$ (415.1)	0.3	1,551.4	(385.6)	2,470.5	0.1
Beginning balance (in shares) at Oct. 31, 2018		49.2	3.6
Beginning balance at Oct. 31, 2018	3,307.8	$ 5	$ (415.1)	0.3	1,572.1	(430.7)	2,576	0.2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	103.2						103.2
Other comprehensive income (loss), net of tax	32.7					32.7
Issuance of common stock for stock plans, net (in shares)		0.1
Issuance of common stock for stock plans, net	(9)				(9)
Treasury stock repurchase	(6.1)
Dividends on common stock	(1.5)						(1.5)
Share-based compensation expense	11.7				11.7
Ending balance (in shares) at Jan. 31, 2019		49.3	3.6
Ending balance at Jan. 31, 2019	3,425.5	$ 5	$ (421.2)	0.3	1,574.8	(398)	2,664.4	0.2
Beginning balance (in shares) at Oct. 31, 2018		49.2	3.6
Beginning balance at Oct. 31, 2018	3,307.8	$ 5	$ (415.1)	0.3	1,572.1	(430.7)	2,576	0.2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	345.7
Ending balance (in shares) at Jul. 31, 2019		49.6	3.6
Ending balance at Jul. 31, 2019	3,615.5	$ 5	$ (421.2)	0.3	1,607.6	(481.8)	2,905.4	0.2
Beginning balance (in shares) at Jan. 31, 2019		49.3	3.6
Beginning balance at Jan. 31, 2019	3,425.5	$ 5	$ (421.2)	0.3	1,574.8	(398)	2,664.4	0.2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	122.4						122.4
Other comprehensive income (loss), net of tax	(18.6)					(18.6)
Issuance of common stock for stock plans, net (in shares)		0.2
Issuance of common stock for stock plans, net	4.5				4.5
Share-based compensation expense	8.4				8.4
Ending balance (in shares) at Apr. 30, 2019		49.5	3.6
Ending balance at Apr. 30, 2019	3,542.2	$ 5	$ (421.2)	0.3	1,587.7	(416.6)	2,786.8	0.2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	120.1						120.1
Other comprehensive income (loss), net of tax	(65.2)					(65.2)
Issuance of common stock for stock plans, net (in shares)		0.1
Issuance of common stock for stock plans, net	12.2				12.2
Dividends on common stock	(1.5)						(1.5)
Share-based compensation expense	7.7				7.7
Ending balance (in shares) at Jul. 31, 2019		49.6	3.6
Ending balance at Jul. 31, 2019	$ 3,615.5	$ 5	$ (421.2)	$ 0.3	$ 1,607.6	$ (481.8)	$ 2,905.4	$ 0.2

Consolidated Condensed Statem_2

Consolidated Condensed Statements of Cash Flows - USD ($) $ in Millions	9 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Cash flows from operating activities:
Net income	$ 345.7	$ 39.2
Depreciation and amortization	210.2	204.6
Gain on sale of an intangible (Note 5)	(19)	0
Impairment of intangibles	0	24.4
Increase in operating capital	(22.1)	(141.1)
Other non-cash items	(1.5)	305.2
Net cash provided by operating activities	513.3	432.3
Cash flows from investing activities:
Purchases of property, plant and equipment	(207.3)	(150.2)
Acquisitions of businesses and assets, net of cash acquired, and other	(59.1)	(1,320.8)
Net cash used in investing activities	(266.4)	(1,471)
Cash flows from financing activities:
Proceeds from long-term debt	576.8	2,073.1
Repayments of long-term debt	(1,140.8)	(971.1)
Net proceeds from short-term debt	351.8	21
Net proceeds related to share-based compensation awards	7.7
Net (payments) related to share-based compensation awards		9.8
Dividends on common stock	(1.5)	(1.5)
Repurchase of common stock	(6.1)	0
Debt acquisition costs	(0.2)	(3.9)
Payment of contingent consideration	0	(0.1)
Net cash (used in) provided by financing activities	(212.3)	1,107.7
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(1.6)	(2.2)
Net increase in cash, cash equivalents and restricted cash	33	66.8
Cash, cash equivalents and restricted cash at beginning of period	80.2	88.8
Cash, cash equivalents and restricted cash at end of period	113.2	155.6
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Total cash, cash equivalents, and restricted cash	$ 80.2	$ 88.8

General

General	9 Months Ended
	Jul. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
General	General The accompanying unaudited interim consolidated condensed financial statements and related notes should be read in conjunction with the audited Consolidated Financial Statements of the Cooper Companies, Inc. and its subsidiaries (the Company) and related notes as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended October 31, 2018. The unaudited interim financial statements include all adjustments (consisting only of normal recurring adjustments) and accruals necessary in the judgment of management for a fair statement of the results for the periods presented. Readers should not assume that the results reported here either indicate or guarantee future performance. The terms "the Company", "we", "us", and "our" are used to refer collectively to the Cooper Companies, Inc. and its subsidiaries. Accounting Pronouncements Recently Adopted In July 2019, the FASB issued ASU 2019-07, Codification Updates to SEC Sections . The ASU clarifies or improves the disclosure and presentation requirements of a variety of codification topics by aligning them with the SEC’s regulations, thereby eliminating redundancies and making the codification easier to apply. The Company adopted this guidance during third quarter of fiscal 2019, and it did not have a material impact on the Company’s reported consolidated financial results. In March 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost . The ASU requires an entity to disaggregate the service cost component from the other components of net benefit cost. The service cost component is now presented in the same income statement line as other compensation costs arising from services rendered by the pertinent employees during the period and the other components of net benefit costs are presented separately as other income/expense below operating income. The Company adopted this guidance on November 1, 2018, and it did not have a material impact on the Company’s reported consolidated financial results. In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory , which requires entities to recognize the income tax consequences on an intra-entity transfer of an asset other than inventory when the transfer occurs. The ASU changes the timing of the recognition of the income tax consequences of non-inventory transfers which under previous guidance deferred the income tax consequences until the asset was sold to an outside party or otherwise recognized. The guidance for the amendments of ASU 2016-16 requires companies to apply a modified retrospective approach with a cumulative catch-up adjustment to opening retained earnings in the period of adoption. The Company adopted ASU 2016-16 in the first quarter of fiscal 2019 on a modified retrospective basis. The Company recorded the cumulative effect of the change as a decrease to retained earnings of approximately $13.3 million . The cumulative effect adjustment represents the recognition of unrecognized income tax effects from intra-entity transfers of assets other than inventory that occurred prior to the date of adoption. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The ASU requires revenue recognition to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The amendments in the ASU can be applied either retrospectively to each prior reporting period presented or alternatively, the modified retrospective transition method whereby the company recognizes the cumulative effect of initially applying the guidance as an opening balance sheet adjustment to equity in the period of initial application. This alternative approach must be supplemented by additional disclosures. We adopted ASU 2014-09 on November 1, 2018, using the modified retrospective transition method. We did not recognize any cumulative effect of initially applying the new revenue standard as an adjustment to our opening balance of retained earnings due to its immaterial impact. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods. There was no material impact of ASU 2014-09 to our financial statements during the three and nine months ended July 31, 2019 . We do not expect the adoption of the new revenue standard to have a material impact to our net income on an ongoing basis. The Company applies the provisions of Accounting Standards Codification (ASC) 606-10 or ASU 2014-09, Revenue from Contracts with Customers , and all related appropriate guidance. The Company recognizes revenue under the core principle to depict the transfer of control to the Company’s customers in an amount reflecting the consideration to which the Company expects to be entitled. In order to achieve that core principle, the Company applies the following five step approach: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when a performance obligation is satisfied. For a complete discussion of accounting for net product revenue, see Note 2. Revenue Recognition. Accounting Pronouncements Issued Not Yet Adopted In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808), Clarifying the Interaction between Topic 808 and Topic 606 . This guidance amended Topic 808 and Topic 606 to clarify that transactions in a collaborative arrangement should be accounted for under Topic 606 when the counterparty is a customer for a distinct good or service (i.e., unit of account). The amendments preclude an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. We are currently evaluating the impact of ASU 2018-18 which is effective for the Company in our fiscal year and interim periods beginning on November 1, 2020. In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other - Internal Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract. This guidance requires companies to apply the internal-use software guidance in ASC 350-40 to implementation costs incurred in a hosting arrangement that is a service contract to determine whether to capitalize certain implementation costs or expense them as incurred. We are currently evaluating the impact of ASU 2018-15 which is effective for the Company in our fiscal year and interim periods beginning on November 1, 2020. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) . ASU 2016-02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use (ROU) asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. In July 2018, the FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases and ASU 2018-11, Leases Topic 842 Target improvements , which provides an additional (and optional) transition method whereby the new lease standard is applied at the adoption date and recognized as an adjustment to retained earnings. In March 2019, the FASB issued ASU 2019-01, Leases (Topic 842) Codification Improvements , which further clarifies the determination of fair value of the underlying asset by lessors that are not manufacturers or dealers and modifies transition disclosure requirements for changes in accounting principles and other technical updates. This standard is effective for the Company in our fiscal year and interim periods beginning on November 1, 2019. We anticipate this standard to have a material impact on our Consolidated Balance Sheets and related disclosures due to the recognition of ROU assets and lease liabilities for operating leases. However, we do not expect the adoption to have a material impact on our Consolidated Statements of Income. We are continuing to assess and evaluate the potential impacts of the standard as well as the election of transition method and certain practical expedients available within ASU 2019-01. We are in the process of documenting and analyzing our lease contracts, assessing business processes and controls, implementing a system solution and completing our analysis of information necessary to determine the impact to the consolidated financial statements.

Revenue Recognition

Revenue Recognition	9 Months Ended
	Jul. 31, 2019
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition Product Revenue, Net The Company sells its products principally to a limited number of distributors, group purchasing organizations, eye care or health care professionals including independent practices, corporate retailers, hospitals and clinics or authorized resellers (collectively, its Customers). These Customers subsequently resell the Company’s products to eye care or health care providers and patients. In addition to product supply and distribution agreements with Customers, the Company enters into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of the Company’s products. The Company considers customer purchase orders, which in some cases are governed by master sales agreements, to be contracts with a customer. In situations where sales are to a distributor, the Company has concluded that its contracts are with the distributor. As part of its consideration of the contract, the Company evaluates certain factors including the customer’s ability to pay (or credit risk). For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations. Revenues from product sales are recognized when the Customer obtains control of the Company’s product, which occurs at a point in time, typically upon shipment or delivery to the Customer. When the Company performs shipping and handling activities after the transfer of control to the Customer (e.g., when control transfers prior to delivery), they are considered as fulfillment activities, and accordingly, the costs are accrued for when the related revenue is recognized. Taxes collected from Customers relating to product sales and remitted to governmental authorities are excluded from revenues. The Company does not have any revenue recognized on payment expected to be received more than one year after the transfer of control of the products. The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that the Company would have recognized is one year or less. See Note14. Business Segment Information, for disaggregation of revenue. Reserves for Variable Consideration Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from discounts, returns, chargebacks, rebates and other allowances that are offered within contracts between the Company and its Customers, health care providers, payors and other indirect customers relating to the Company’s sales of its products. These reserves are based on the amounts earned or to be claimed on the related sales and are classified primarily in current liabilities. Variable consideration is estimated based on the most likely amount or expected value approach, depending on which method the Company expects to better predict the amount of consideration to which it will be entitled. Once the Company elects one of the methods to estimate variable consideration for a particular type of performance obligation, the Company applies that method consistently. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known. Trade Discounts and Allowances The Company generally provides Customers with discounts, which include incentive fees that are stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company receives sales order management, data and distribution services from certain Customers. To the extent the services received are distinct from the Company’s sale of products to the Customer and have readily determinable fair value, these payments are classified in selling, general and administrative expenses in the Consolidated Statements of Income of the Company. Product Returns Consistent with industry practice, the Company generally offers Customers a limited right of return for a product that has been purchased from the Company. The Company estimates the amount of its product sales that may be returned by its Customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. There is inherent judgment in estimating future refunds as they are susceptible to factors outside of our influence. However, we have significant experience in estimating the amount of refunds, based primarily on historical data. Our refund liability for product returns was $9.9 million at July 31, 2019 which is included in Accrued Liabilities on our Condensed Consolidated Balance Sheets and represents the expected value of the aggregate refunds that will be due to our customers. Rebates and Chargebacks Rebates are estimated based on contractual terms, historical experience, customer mix, trend analysis and projected market conditions in the various markets served. Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list wholesale prices charged to the Company’s direct customers. For certain office and surgical products in CooperSurgical, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by Customers. CooperSurgical rebates are predominately related to the Medicaid rebate provision that is estimated based upon contractual terms, historical experience, and trend analysis. Contract balances The timing of billing and revenue recognition primarily occurs simultaneously. The Company does not have material contract assets or liabilities.

Acquisitions

Acquisitions	9 Months Ended
	Jul. 31, 2019
Business Combination And Asset Acquisition [Abstract]
Acquisitions	Acquisitions The following is a summary of the allocation of the total purchase consideration for business and asset acquisitions that the Company completed during fiscal 2019 and 2018: (In millions) July 31, 2019 October 31, 2018 Technology $ 12.3 $ — Customer relationships 7.5 23.5 Trademarks 10.2 100.0 Composite intangible asset — 1,061.9 Other 0.1 4.2 Total identifiable intangible assets $ 30.1 $ 1,189.6 Goodwill 35.8 70.6 Net tangible assets 1.3 59.6 Total purchase price $ 67.2 $ 1,319.8 All the acquisitions were funded by cash generated from operations or facility borrowings. For business acquisitions, we recorded the tangible and intangible assets acquired and liabilities assumed at their fair values as of the applicable date of acquisition. For assets acquisitions, we recorded the tangible and intangible assets acquired and liabilities assumed at their estimated and relative fair values as of the applicable date of acquisition. We believe these acquisitions strengthen CooperSurgical's and CooperVision's businesses through the addition of new or complementary products and services. Fiscal Year 2019 On December 31, 2018, CooperSurgical completed the acquisition of Incisive Surgical Inc., a privately-held U.S. medical device company that develops mechanical surgical solutions for skin closure. The purchase price allocation is preliminary and we are in the process of finalizing information primarily related to taxes and the corresponding impact on goodwill. On December 28, 2018, CooperVision completed the acquisition of Blanchard Contact Lenses. Blanchard is a privately-held scleral lens company, which expands CooperVision's specialty and scleral lens portfolio. The purchase price allocation is preliminary and we are in the process of finalizing information primarily related to property plant and equipment, taxes and the corresponding impact on goodwill. The pro forma results of operations of these acquisitions have not been presented because the effects of the business combinations described above, individually and in the aggregate, were not material to our reported consolidated financial results. Fiscal Year 2018 PARAGARD On November 1, 2017, CooperSurgical acquired the assets of the PARAGARD Intrauterine Device (IUD) business (PARAGARD) from Teva Pharmaceuticals Industries Limited for $1.1 billion . This asset acquisition broadened and strengthened CooperSurgical's product portfolio. PARAGARD ® is the only hormone-free, long lasting, reversible contraceptive approved by the United States Food and Drug Administration (FDA) available in the United States. The following table summarizes the relative fair values of net assets acquired and liabilities assumed using the cost accumulation and allocation model: (In millions) Relative Fair Value Composite intangible asset (1) $ 1,061.9 Assembled workforce intangible asset (2) 1.2 Property, plant and equipment 2.0 Inventory (3) 47.3 Other assets 9.4 Total assets acquired $ 1,121.8 Less: liabilities assumed 16.4 Total Purchase Price $ 1,105.4 The Company proportionally allocated the acquisition costs to the net assets acquired. The acquisition-related costs included advisory, legal, valuation and other professional fees. (1) Composite Intangible asset consists of technology, trade name, New Drug Application (NDA) approval and physician relationships, which have been valued as a single composite intangible asset as they are inextricably linked. The composite asset was identified as the primary asset acquired, was valued using the Multi-Period Excess Earnings Method and will be amortized over 15 years . (2) An assembled workforce was recognized as a separate acquired intangible asset, given the purchase of assets and will be amortized over 5 years . (3) Inventory relative fair value includes step up of $45.4 million . Other Acquisitions On April 3, 2018, CooperSurgical completed the acquisition of The LifeGlobal Group (LifeGlobal). LifeGlobal was a privately held company that specializes primarily in in-vitro fertilization (IVF) media. LifeGlobal’s product categories include media products as well as IVF laboratory air filtration products and dishware. We have completed the purchase price allocation for this acquisition. On January 4, 2018, CooperVision acquired Blueyes Ltd, a long-standing distribution partner, with a leading position in the distribution of contact lenses to the Optical and Pharmacy sector in Israel. We have completed the purchase price allocation for this acquisition. On December 1, 2017, CooperVision acquired Paragon Vision Sciences, a leading provider of orthokeratology (ortho-k) specialty contact lenses and oxygen permeable rigid contact lens materials. Ortho-k contact lenses are overnight lenses which enable corneal topography correction for myopia (nearsightedness) patients. We have completed the purchase price allocation for this acquisition.

Inventories

Inventories	9 Months Ended
	Jul. 31, 2019
Inventory Disclosure [Abstract]
Inventories	Inventories (In millions) July 31, 2019 October 31, 2018 Raw materials $ 127.1 $ 112.5 Work-in-process 13.4 12.6 Finished goods 361.6 343.7 $ 502.1 $ 468.8 Inventories are stated at the lower of cost and net realizable value. Cost is computed using standard cost that approximates actual cost, on a first-in, first-out basis.

Intangible Assets

Intangible Assets	9 Months Ended
	Jul. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets	Intangible Assets Goodwill (In millions) CooperVision CooperSurgical Total Balance at October 31, 2017 $ 1,735.7 $ 619.1 $ 2,354.8 Net additions during the year ended October 31, 2018 36.8 34.4 71.2 Translation (29.6 ) (4.3 ) (33.9 ) Balance at October 31, 2018 1,742.9 649.2 2,392.1 Net additions during the nine months ended July 31, 2019 13.8 22.0 35.8 Translation (33.0 ) (3.5 ) (36.5 ) Balance at July 31, 2019 $ 1,723.7 $ 667.7 $ 2,391.4 Effective April 30, 2019, there was a change in the reporting units as a result of realignment in the internal reporting structure of the business around markets and customers at CooperSurgical. As such, Cooper Surgical has evolved into two reporting units, namely, Office/Surgical and Fertility, which reflects management oversight of operations. The change in reporting units did not result in a change in operating segments. We allocated CooperSurgical's goodwill based on relative fair values utilizing the discounted cash flow method and guideline public company method as our allocation base, and the allocated fair values exceeded the carrying values for each of the three reporting units as of April 30, 2019. We evaluate goodwill for impairment annually during the fiscal third quarter and when an event occurs or circumstances change such that it is reasonably possible that impairment may exist. We account for goodwill and evaluate our goodwill balances and test them for impairment in accordance with related accounting standards. We performed our annual impairment assessment in our third quarter of fiscal 2019 and 2018, and our analysis indicated that we had no impairment of goodwill in our reporting units. We performed a qualitative assessment to test each reporting unit's goodwill for impairment. Qualitative factors considered in this assessment include industry and market considerations, overall financial performance and other relevant events and factors affecting each reporting unit. Based on our qualitative assessment, if we determine that the fair value of a reporting unit is more likely than not to be less than its carrying amount, the fair value of a reporting unit will be compared with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value of the reporting unit. A reporting unit is the level of reporting at which goodwill is tested for impairment. Our reporting units are CooperVision, Office/Surgical and Fertility reflecting the current way we manage our business. Goodwill impairment analysis and measurement is a process that requires significant judgment. If our common stock price trades below book value per share, there are changes in market conditions or a future downturn in our business, or a future goodwill impairment test indicates an impairment of our goodwill, we may have to recognize a non-cash impairment of goodwill that could be material and could adversely affect our results of operations in the period recognized and also adversely affect our total assets and stockholders' equity. Other Intangible Assets July 31, 2019 October 31, 2018 (In millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Weighted Average Amortization Period (In years) Intangible assets with definite lives: Trademarks $ 148.3 $ 24.6 $ 138.1 $ 16.9 14 Composite intangible asset 1,061.9 123.9 1,061.9 70.8 15 Technology 398.8 213.0 387.2 190.7 11 Customer relationships 356.1 187.0 350.0 168.6 13 License and distribution rights and other (1) 27.8 14.7 74.9 52.7 11 1,992.9 $ 563.2 2,012.1 $ 499.7 14 Less: accumulated amortization and translation 563.2 499.7 Intangible assets with definite lives, net 1,429.7 1,512.4 Intangible assets with indefinite lives, net (2) 8.9 8.9 Total other intangible assets, net $ 1,438.6 $ 1,521.3 (1) In the second quarter of fiscal 2019, CooperSurgical sold an exclusive distribution right to distribute Filshie Clip System in the U.S. for $21.0 million and recognized a gain of $19.0 million . In the third quarter of fiscal 2019, CooperVision removed $37.3 million of fully amortized non-compete agreements. (2) Intangible assets with indefinite lives include trademark and technology intangible assets. Balances include foreign currency translation adjustments. As of July 31, 2019, the estimation of amortization expenses for intangible assets with definite lives is as follows: Fiscal years: (In millions) Remainder of 2019 $ 35.1 2020 135.6 2021 134.3 2022 132.4 2023 130.2 Thereafter 862.1 Total remaining amortization for intangible assets with definite lives $ 1,429.7 The Company assesses definite-lived intangible assets whenever events or changes in circumstances indicate that the carrying amount of a definite-lived intangible asset (asset group) may not be recoverable. When events or changes in circumstances indicate that the carrying amount of a definite-lived intangible asset may not be recoverable, the Company evaluates whether the definite-lived intangible asset is impaired by comparing its carrying value to its undiscounted future cash flows. The Company assesses indefinite-lived intangible assets annually in the third quarter of the fiscal year, or whenever events or circumstances indicate that the carrying amount of an indefinite-lived intangible asset (asset group) may not be recoverable. The Company evaluates whether the indefinite-lived intangible asset is impaired by comparing its carrying value to its fair value. If the carrying value of a definite-lived or indefinite-lived intangible asset is not recoverable, an impairment loss is recognized based on the amount by which the carrying value exceeds the fair value. The inputs used in the fair value analysis fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. The Company did not recognize any material definite-lived or indefinite-lived intangible asset impairment charges during the three and nine months ended July 31, 2019.

Debt

Debt	9 Months Ended
	Jul. 31, 2019
Debt Disclosure [Abstract]
Debt	Debt (In millions) July 31, 2019 October 31, 2018 Overdraft and other credit facilities $ 65.0 $ 37.1 Term loans 325.0 — Short-term Debt $ 390.0 $ 37.1 Revolving credit $ — $ 439.0 Term loans 1,425.0 1,550.0 Other 0.2 0.2 Less: unamortized debt issuance cost (2.6 ) (3.5 ) Long-term Debt $ 1,422.6 $ 1,985.7 Total Debt $ 1,812.6 $ 2,022.8 $400 million Term Loan on November 1, 2018 On November 1, 2018, the Company entered into a 364 -day, $400.0 million , senior unsecured term loan agreement by and among the Company, the lenders party thereto and PNC Bank, National Association, as administrative agent which matures on October 31, 2019 (the 2018 Term Loan Agreement). The Company used the funds to partially repay outstanding borrowings under the 2016 Revolving Credit Facility. At July 31, 2019 , we had $325.0 million outstanding under the 2018 Term Loan Agreement. Amounts outstanding under the 2018 Term Loan Agreement will bear interest, at the Company's option, at either the base rate, or the adjusted LIBO rate (each as defined in the 2018 Term Loan Agreement), plus, in each case, an applicable rate of 0.00% in respect of base rate loans and 0.60% in respect of adjusted LIBO rate loans. The weighted average interest rate for the three months and nine months ended July 31, 2019 were 3.02% and 3.04% , respectively. The 2018 Term Loan Agreement contains customary restrictive covenants, as well as financial covenants that require the Company to maintain a certain Total Leverage Ratio and Interest Coverage Ratio (each as defined in the 2018 Term Loan Agreement) consistent with the 2016 Credit Agreement discussed below. $1.425 billion Term Loan on November 1, 2017 On November 1, 2017, in connection with the PARAGARD acquisition, we entered into a five -year, $1.425 billion , senior unsecured term loan agreement (the 2017 Term Loan Agreement) by and among the Company, the lenders party thereto and DNB Bank ASA, New York Branch, as administrative agent which matures on November 1, 2022. The Company used part of the facility to fund the PARAGARD acquisition and used the remainder of the funds to partially repay outstanding borrowings under our revolving credit agreement. Amounts outstanding under the 2017 Term Loan Agreement will bear interest, at our option, at either the base rate, or the adjusted LIBO rate (each as defined in the 2017 Term Loan Agreement), plus, in each case, an applicable rate of, between 0.00% and 0.75% in respect of base rate loans and between 1.00% and 1.75% in respect of adjusted LIBO rate loans, in each case in accordance with a pricing grid tied to the Total Leverage Ratio as defined in the 2017 Term Loan Agreement. The 2017 Term Loan Agreement contains customary restrictive covenants, as well as financial covenants that require the Company to maintain a certain Total Leverage Ratio and Interest Coverage Ratio (each as defined in the 2017 Term Loan Agreement) consistent with the 2016 Credit Agreement discussed below. At July 31, 2019 , we had $1.425 billion outstanding under the 2017 Term Loan Agreement. The interest rate on the 2017 term loan was 3.36% at July 31, 2019. Revolving Credit and Term Loan Agreement on March 1, 2016 On March 1, 2016 , we entered into a Revolving Credit and Term Loan Agreement (the 2016 Credit Agreement), among the Company, CooperVision International Holding Company, LP, the lenders party thereto and KeyBank National Association, as administrative agent. The 2016 Credit Agreement provides for a multicurrency revolving credit facility in an aggregate principal amount of $1.0 billion (the 2016 Revolving Credit Facility) and a term loan facility in an aggregate principal amount of $830.0 million (the 2016 Term Loan Facility), each of which, unless terminated earlier, mature on March 1, 2021 . In addition, we have the ability from time to time to request an increase to the size of the 2016 Revolving Credit Facility or establish one or more new term loans under the 2016 Term Loan Facility in an aggregate amount up to $750.0 million , subject to the discretionary participation of the lenders. Amounts outstanding under the 2016 Credit Agreement will bear interest, at our option, at either the base rate, or the adjusted LIBO rate or adjusted foreign currency rate (each as defined in the 2016 Credit Agreement), plus, in each case, an applicable rate of between 0.00% and 0.75% in respect of base rate loans and between 1.00% and 1.75% in respect of adjusted LIBO rate or adjusted foreign currency rate loans, in each case in accordance with a pricing grid tied to the Total Leverage Ratio, as defined in the 2016 Credit Agreement. We pay an annual commitment fee that ranges from 0.125% to 0.25% of the unused portion of the 2016 Revolving Credit Facility depending on certain financial ratios. In addition to the annual commitment fee described above, we are also required to pay certain letter of credit and related fronting fees and other administrative fees pursuant to the terms of the 2016 Credit Agreement. At July 31, 2019 , we had no outstanding balance under the 2016 Term Loan Facility and $998.8 million available under the 2016 Revolving Credit Facility. The 2016 Credit Agreement contains customary restrictive covenants, as well as financial covenants that require us to maintain a certain Total Leverage Ratio and Interest Coverage Ratio (each as defined in the 2016 Credit Agreement): • Interest Coverage Ratio, as defined, to be at least 3.00 to 1.00 at all times. • Total Leverage Ratio, as defined, to be no higher than 3.75 to 1.00 . At July 31, 2019 , we were in compliance with the Interest Coverage Ratio at 12.24 to 1.00 and the Total Leverage Ratio at 1.83 to 1.00 for 2018 Term Loan Agreement, the 2017 Term Loan Agreement, and the 2016 Credit Agreement. Refer to our Annual Report on Form 10-K for the fiscal year ended October 31, 2018

Income Taxes

Income Taxes	9 Months Ended
	Jul. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes Recent Tax Legislation The 2017 Act was enacted into law on December 22, 2017 and significantly changed existing U.S. tax law. The 2017 Act adopted a territorial tax system, imposed a mandatory one-time transition tax on earnings of foreign subsidiaries that were previously indefinitely reinvested, and reduces the U.S. federal statutory tax rate from 35% to 21%. For third quarter of fiscal 2019, the Company has utilized the enacted U.S. federal statutory tax rate of 21%. The 2017 Act includes several provisions that are effective for our fiscal 2019: (i) tax on global intangible low-taxed income (GILTI) of foreign subsidiaries, (ii) tax on certain payments between a U.S. corporation and its foreign subsidiaries referred to as the base erosion and anti-abuse tax (BEAT), (iii) limitation on the tax deduction for interest payments, and (iv) expanded limitation on the tax deduction for compensation paid to certain executives. The 2017 Act was effective in the first quarter of fiscal 2018. During the first quarter of fiscal 2019, we recorded tax benefit of $4.4 million in our financial statements to finalize the tax effects of the 2017 Act pursuant to SAB 118. The Company is no longer asserting that earnings from our foreign subsidiaries are indefinitely reinvested. The 2017 Act imposes a new tax on foreign earnings and profits in excess of a deemed return on tangible assets of foreign subsidiaries referred to as GILTI which is effective in fiscal 2019. In accordance with FASB Staff Q&A, Topic 740, No. 5, Accounting for Global Intangible Low-Taxed Income , the Company made an accounting policy election to recognize the tax expense related to GILTI in the year the tax is incurred. Effective Tax Rate The Company's effective tax rates were an expense of 5.4% and a benefit of 11.5% for the third quarter of fiscal 2019 and fiscal 2018, respectively, and an expense of 0.9% and 82.1% for the first nine months of fiscal 2019 and 2018, respectively. The increase in our effective tax rate for the third quarter of fiscal 2019 compared to fiscal 2018 was primarily due to the inclusion of earnings from our foreign subsidiaries pursuant to the GILTI provisions that became effective in fiscal 2019. The decrease in our effective tax rate for the first nine months of fiscal 2019 compared to fiscal 2018 was primarily due to the provisional charge of $196.7 million relating to the 2017 Act that was recorded in fiscal 2018. Our effective tax rate for the first nine months of fiscal 2019 was lower than the U.S. statutory rate because of discrete tax benefits and a favorable mix of income from our foreign jurisdictions with lower tax rates. Total discrete tax benefits for the first nine months of fiscal 2019 were $26.7 million primarily relating to settlement of tax audits, revisions to the provisional tax charges relating to the 2017 Act, and excess tax benefits from share-based compensation. Our effective tax rate for the first nine months of fiscal 2018 was higher than the U.S. statutory rate because of the discrete tax expense relating to the 2017 Act, which was partially offset by a favorable mix of income from our foreign jurisdictions with lower tax rates and an excess tax benefit from share-based compensation. We recognize the benefit from a tax position only if it is more likely than not that the position would be sustained upon audit based solely on the technical merits of the tax position. As of July 31, 2019, and October 31, 2018, Cooper had unrecognized tax benefits of $50.7 million and $68.9 million , respectively. The decrease is primarily related to settling prior year tax audits, partially offset by additions to current period transfer pricing reserves. It is our policy to recognize interest and penalties directly related to income taxes as additional income tax expense. It is reasonably possible that $8.1 million of unrecognized tax benefits could be settled during the next twelve months. The Company is subject to U.S. Federal income tax examinations for fiscal 2015 through 2018 and the Internal Revenue Service is currently auditing our U.S. Consolidated Corporation Income Tax Returns for fiscal 2015 and 2016. The Company remains subject to income tax examinations in other significant tax jurisdictions including the United Kingdom, Japan, France and Australia for the tax years 2015 through 2018.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Jul. 31, 2019
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Periods Ended July 31, Three Months Nine Months (In millions, except per share amounts) 2019 2018 2019 2018 Net income $ 120.1 $ 100.8 $ 345.7 $ 39.2 Basic: Weighted average common shares 49.5 49.1 49.4 49.0 Basic earnings per share $ 2.43 $ 2.05 $ 7.00 $ 0.80 Diluted: Weighted average common shares 49.5 49.1 49.4 49.0 Effect of potential dilutive shares 0.6 0.6 0.6 0.6 Diluted weighted average common shares 50.1 49.7 50.0 49.6 Diluted earnings per share attributable to Cooper stockholders $ 2.40 $ 2.03 $ 6.91 $ 0.79 The following table sets forth stock options to purchase Cooper’s common stock and restricted stock units that were not included in the diluted earnings per share calculation because their effect would have been antidilutive for the periods presented: Periods Ended July 31, Three Months Nine Months (In thousands, except exercise prices) 2019 2018 2019 2018 Number of stock option shares excluded — 257 198 257 Range of exercise prices n/a $226.30-$230.09 $ 254.77 $226.30-$230.09 Numbers of restricted stock units excluded 18 78 19 78

Share-Based Compensation Plans

Share-Based Compensation Plans	9 Months Ended
	Jul. 31, 2019
Share-based Payment Arrangement [Abstract]
Share-Based Compensation Plans	Share-Based Compensation Plans The Company has several share-based compensation plans that are described in the Company’s Annual Report on Form 10‑K for the fiscal year ended October 31, 2018 . The compensation expense and related income tax benefit recognized in our Consolidated Condensed Statements of Income for share-based awards were as follows: Periods Ended July 31, Three Months Nine Months (In millions) 2019 2018 2019 2018 Selling, general and administrative expense $ 6.8 $ 6.7 $ 22.1 $ 30.3 Cost of sales 1.0 0.9 3.9 2.6 Research and development expense 0.5 0.5 2.4 1.6 Total share-based compensation expense $ 8.3 $ 8.1 $ 28.4 $ 34.5 Related income tax benefit $ 1.1 $ 1.5 $ 4.0 $ 7.1 Employee Stock Purchase Plan On March 18, 2019, the Company received stockholder approval for the Employee Stock Purchase Plan (“ESPP”). The first offering period is for U.S. employees and is expected to begin on November 4, 2019. The purpose of the ESPP is to provide eligible employees of the Company with the opportunity to acquire shares of common stock at 85% of the market price on the last business day of each offering period by means of accumulated payroll deductions. Payroll deductions will be limited to maximum of 15% of the employee’s eligible compensation, not to exceed $21.3 thousand in any one calendar year. The ESPP would initially authorize the issuance of 1,000,000 shares of common stock. These shares will be made available from shares of common stock reacquired by the Company as Treasury Stock. At July 31, 2019, there were approximately 3.6 million shares of Treasury Stock.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Jul. 31, 2019
Stockholders' Equity Note [Abstract]
Stockholders' Equity	Stockholders’ Equity Analysis of Changes in Accumulated Other Comprehensive (Loss) Income: (In millions) Foreign Currency Translation Adjustment Minimum Pension Liability Total Balance at October 31, 2017 $ (353.7 ) $ (21.6 ) $ (375.3 ) Gross change in value during the year ended October 31, 2018 (58.5 ) 11.0 (47.5 ) Tax effect for the period — (3.1 ) (3.1 ) ASU 2018-02 adoption (1) — (4.8 ) (4.8 ) Balance at October 31, 2018 $ (412.2 ) $ (18.5 ) $ (430.7 ) Gross change in value during the nine months ended July 31, 2019 (51.1 ) — (51.1 ) Balance at July 31, 2019 $ (463.3 ) $ (18.5 ) $ (481.8 ) (1) Represents reclassification to retained earnings from adoption of ASU 2018-02. Refer to our Annual Report on Form 10-K for the fiscal year ended October 31, 2018 for more details. Share Repurchases In December 2011, our Board of Directors authorized the 2012 Share Repurchase Program and through subsequent amendments, the most recent in March 2017, the total repurchase authorization was increased from $500.0 million to $1.0 billion of the Company's common stock. This program has no expiration date and may be discontinued at any time. Purchases under the 2012 Share Repurchase Program are subject to a review of the circumstances in place at the time and may be made from time to time as permitted by securities laws and other legal requirements. We did no t repurchase shares in the third and second quarters of fiscal 2019. During the first quarter of fiscal 2019, we repurchased 24.5 thousand shares of the Company's common stock for $6.1 million , at an average purchase price of $248.70 per share. We did no t repurchase shares during the fiscal year ended October 31, 2018. At July 31, 2019 , $557.4 million remains authorized for repurchase under the program. Dividends We paid a semiannual dividend of approximately $1.5 million or 3 cents per share on February 8, 2019, to stockholders of record on January 22, 2019 . We paid another semiannual dividend of approximately $1.5 million or 3 cents

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Jul. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Accounting standards define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value. An asset’s or liability’s level is based on the lowest level of input that is significant to the fair value measurement. Assets and liabilities carried at fair value are valued and disclosed in one of the following three levels of the valuation hierarchy: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions. At July 31, 2019 and October 31, 2018 , the carrying value of cash and cash equivalents, accounts receivable, prepaid expense and other current assets, lines of credit, accounts payable and other current liabilities approximate fair value due to the short-term nature of such instruments and the ability to obtain financing on similar terms. The carrying value of our revolving credit facility and term loans approximates fair value estimated based on current market rates (Level 2). The Company did no t have any derivative assets or liabilities that may include interest rate swaps, cross currency swaps or foreign currency forward contracts as of July 31, 2019 and October 31, 2018 . Nonrecurring fair value measurements The Company uses fair value measures when determining assets and liabilities acquired in an acquisition as described in Note 3. Acquisitions which are considered a Level 3 measurement. The Company also used fair value measures to allocate goodwill upon the split of our reporting units as discussed in Note 5. Intangible Assets which was considered a Level 3 measurement.

Employee Benefits

Employee Benefits	9 Months Ended
	Jul. 31, 2019
Retirement Benefits [Abstract]
Employee Benefits	Employee Benefits Cooper’s Retirement Income Plan (the Plan), a defined benefit plan, covers substantially all full-time United States employees. Our contributions are designed to fund normal cost on a current basis and to fund the estimated prior service cost of benefit improvements. The unit credit actuarial cost method is used to determine the annual cost. Cooper pays the entire cost of the Plan and funds such costs as they accrue. Virtually all of the assets of the Plan are comprised of equities and participation in equity and fixed income funds. Our results of operations for the three and nine months ended July 31, 2019 and 2018 , reflect the following components of net periodic defined benefit costs: Periods Ended July 31, Three Months Nine Months (In millions) 2019 2018 2019 2018 Service cost $ 2.2 $ 2.7 $ 7.6 $ 8.1 Interest cost 2.1 1.3 4.6 3.8 Expected return on plan assets (2.8 ) (2.3 ) (7.4 ) (6.9 ) Recognized net actuarial loss (0.2 ) 0.4 0.6 1.2 Net periodic pension cost $ 1.3 $ 2.1 $ 5.4 $ 6.2 We contributed $5.0 million to the Plan in the first nine months of fiscal 2019 and 2018. The expected rate of return on Plan assets for determining net periodic benefit plan cost is 8% . Retirement Income Plan Soft Freeze On June 18, 2019 the Board of Directors of the Company approved a soft freeze of the Plan effective August 1, 2019. The Plan was closed to employees hired on or after August 1, 2019, including former participants or employees rehired on or after August 1, 2019 and employees hired in connection with a stock or asset acquisition, merger or other similar transaction on or after August 1, 2019. Existing employees already covered by the Plan, continue to accrue their benefits. There is no material impact on the Company's results of operations, financial position and cash flows for the three and nine months ended July 31, 2019.

Contingencies

Contingencies	9 Months Ended
	Jul. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies Since March 2015, over 50 putative class action complaints were filed by contact lens consumers alleging that contact lens manufacturers, in conjunction with their respective Unilateral Pricing Policy (UPP), conspired to reach agreements between each other and certain distributors and retailers regarding the prices at which certain contact lenses could be sold to consumers. The plaintiffs are seeking damages against CooperVision, Inc., other contact lens manufacturers, distributors and retailers, in various courts around the United States. In June 2015, all of the class action cases were consolidated and transferred to the United States District Court for the Middle District of Florida. In August 2017, CooperVision entered into a settlement agreement with the plaintiffs, without any admission of liability, to settle all claims against CooperVision. In July 2018, the Court approved the plaintiffs’ motion for preliminary approval of the settlement, and the Company paid the $3.0 million settlement amount into an escrow account. The settlement remains subject to final Court approval at a future hearing to be set by the Court. The Company is involved in various lawsuits, claims and other legal matters from time to time that arise in the ordinary course of conducting business, including matters involving our products, intellectual property, supplier relationships, distributors, competitor relationships, employees and other matters. The Company does not believe that the ultimate resolution of these proceedings or claims pending against it could have a material adverse effect on its financial condition or results of operations. At each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies . Legal fees are expensed as incurred.

Business Segment Information

Business Segment Information	9 Months Ended
	Jul. 31, 2019
Segment Reporting [Abstract]
Business Segment Information	Business Segment Information Cooper uses operating income, as presented in our financial reports, as the primary measure of segment profitability. We do not allocate costs from corporate functions to segment operating income. Items below operating income are not considered when measuring the profitability of a segment. We use the same accounting policies to generate segment results as we do for our consolidated results. Total identifiable assets are those used in continuing operations except cash and cash equivalents, which we include as corporate assets. Segment information: Periods Ended July 31, Three Months Nine Months (In millions) 2019 2018 2019 2018 CooperVision net sales by category: Toric lens $ 163.1 $ 153.6 $ 464.4 $ 442.2 Multifocal lens 52.4 52.7 151.1 148.8 Single-use sphere lens 146.3 137.6 413.6 378.3 Non single-use sphere and other 147.3 145.2 434.2 432.1 Total CooperVision net sales 509.1 489.1 1,463.3 1,401.4 CooperSurgical net sales by category: Office and surgical products 106.3 104.4 307.7 290.4 Fertility 64.0 66.5 190.8 189.5 CooperSurgical net sales 170.3 170.9 498.5 479.9 Total net sales $ 679.4 $ 660.0 $ 1,961.8 $ 1,881.3 Operating income (loss): CooperVision $ 134.2 $ 125.4 $ 375.9 $ 361.1 CooperSurgical 20.6 1.6 59.0 (37.5 ) Corporate (12.6 ) (11.4 ) (34.8 ) (43.2 ) Total operating income 142.2 115.6 400.1 280.4 Interest expense 16.7 22.8 53.3 59.9 Other (income) expense, net (1.5 ) 2.4 (2.1 ) 1.3 Income before income taxes $ 127.0 $ 90.4 $ 348.9 $ 219.2 (In millions) [to update] July 31, 2019 October 31, 2018 Total identifiable assets: CooperVision $ 3,801.3 $ 3,746.0 CooperSurgical 2,184.4 2,201.7 Corporate 187.1 165.1 Total $ 6,172.8 $ 6,112.8 Geographic information: Periods Ended July 31, Three Months Nine Months (In millions) 2019 2018 2019 2018 Net sales to unaffiliated customers by country of domicile: United States $ 306.2 $ 302.1 $ 891.1 $ 856.8 Europe 222.7 224.0 642.0 637.8 Rest of world 150.5 133.9 428.7 386.7 Total $ 679.4 $ 660.0 $ 1,961.8 $ 1,881.3 (In millions) July 31, 2019 October 31, 2018 Net property, plant and equipment by country of domicile: United States $ 589.7 $ 516.7 Europe 339.7 340.7 Rest of world 136.0 118.6 Total $ 1,065.4 $ 976.0

General (Policies)

General (Policies)	9 Months Ended
	Jul. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounting Pronouncements Recently Adopted and Accounting Pronouncements Issued Not Yet Adopted	Accounting Pronouncements Recently Adopted In July 2019, the FASB issued ASU 2019-07, Codification Updates to SEC Sections . The ASU clarifies or improves the disclosure and presentation requirements of a variety of codification topics by aligning them with the SEC’s regulations, thereby eliminating redundancies and making the codification easier to apply. The Company adopted this guidance during third quarter of fiscal 2019, and it did not have a material impact on the Company’s reported consolidated financial results. In March 2017, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2017-07, Compensation - Retirement Benefits (Topic 715): Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost . The ASU requires an entity to disaggregate the service cost component from the other components of net benefit cost. The service cost component is now presented in the same income statement line as other compensation costs arising from services rendered by the pertinent employees during the period and the other components of net benefit costs are presented separately as other income/expense below operating income. The Company adopted this guidance on November 1, 2018, and it did not have a material impact on the Company’s reported consolidated financial results. In October 2016, the FASB issued ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory , which requires entities to recognize the income tax consequences on an intra-entity transfer of an asset other than inventory when the transfer occurs. The ASU changes the timing of the recognition of the income tax consequences of non-inventory transfers which under previous guidance deferred the income tax consequences until the asset was sold to an outside party or otherwise recognized. The guidance for the amendments of ASU 2016-16 requires companies to apply a modified retrospective approach with a cumulative catch-up adjustment to opening retained earnings in the period of adoption. The Company adopted ASU 2016-16 in the first quarter of fiscal 2019 on a modified retrospective basis. The Company recorded the cumulative effect of the change as a decrease to retained earnings of approximately $13.3 million . The cumulative effect adjustment represents the recognition of unrecognized income tax effects from intra-entity transfers of assets other than inventory that occurred prior to the date of adoption. In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic 606). The ASU requires revenue recognition to depict the transfer of goods or services to customers at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The amendments in the ASU can be applied either retrospectively to each prior reporting period presented or alternatively, the modified retrospective transition method whereby the company recognizes the cumulative effect of initially applying the guidance as an opening balance sheet adjustment to equity in the period of initial application. This alternative approach must be supplemented by additional disclosures. We adopted ASU 2014-09 on November 1, 2018, using the modified retrospective transition method. We did not recognize any cumulative effect of initially applying the new revenue standard as an adjustment to our opening balance of retained earnings due to its immaterial impact. The comparative information has not been restated and continues to be reported under the accounting standards in effect for those periods. There was no material impact of ASU 2014-09 to our financial statements during the three and nine months ended July 31, 2019 . We do not expect the adoption of the new revenue standard to have a material impact to our net income on an ongoing basis. The Company applies the provisions of Accounting Standards Codification (ASC) 606-10 or ASU 2014-09, Revenue from Contracts with Customers , and all related appropriate guidance. The Company recognizes revenue under the core principle to depict the transfer of control to the Company’s customers in an amount reflecting the consideration to which the Company expects to be entitled. In order to achieve that core principle, the Company applies the following five step approach: (1) identify the contract with a customer, (2) identify the performance obligations in the contract, (3) determine the transaction price, (4) allocate the transaction price to the performance obligations in the contract, and (5) recognize revenue when a performance obligation is satisfied. For a complete discussion of accounting for net product revenue, see Note 2. Revenue Recognition. Accounting Pronouncements Issued Not Yet Adopted In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808), Clarifying the Interaction between Topic 808 and Topic 606 . This guidance amended Topic 808 and Topic 606 to clarify that transactions in a collaborative arrangement should be accounted for under Topic 606 when the counterparty is a customer for a distinct good or service (i.e., unit of account). The amendments preclude an entity from presenting consideration from a transaction in a collaborative arrangement as revenue from contracts with customers if the counterparty is not a customer for that transaction. We are currently evaluating the impact of ASU 2018-18 which is effective for the Company in our fiscal year and interim periods beginning on November 1, 2020. In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other - Internal Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract. This guidance requires companies to apply the internal-use software guidance in ASC 350-40 to implementation costs incurred in a hosting arrangement that is a service contract to determine whether to capitalize certain implementation costs or expense them as incurred. We are currently evaluating the impact of ASU 2018-15 which is effective for the Company in our fiscal year and interim periods beginning on November 1, 2020. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) . ASU 2016-02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use (ROU) asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. In July 2018, the FASB issued ASU 2018-10, Codification Improvements to Topic 842, Leases and ASU 2018-11, Leases Topic 842 Target improvements , which provides an additional (and optional) transition method whereby the new lease standard is applied at the adoption date and recognized as an adjustment to retained earnings. In March 2019, the FASB issued ASU 2019-01, Leases (Topic 842) Codification Improvements , which further clarifies the determination of fair value of the underlying asset by lessors that are not manufacturers or dealers and modifies transition disclosure requirements for changes in accounting principles and other technical updates. This standard is effective for the Company in our fiscal year and interim periods beginning on November 1, 2019. We anticipate this standard to have a material impact on our Consolidated Balance Sheets and related disclosures due to the recognition of ROU assets and lease liabilities for operating leases. However, we do not expect the adoption to have a material impact on our Consolidated Statements of Income. We are continuing to assess and evaluate the potential impacts of the standard as well as the election of transition method and certain practical expedients available within ASU 2019-01. We are in the process of documenting and analyzing our lease contracts, assessing business processes and controls, implementing a system solution and completing our analysis of information necessary to determine the impact to the consolidated financial statements.
Revenue Recognition	Product Revenue, Net The Company sells its products principally to a limited number of distributors, group purchasing organizations, eye care or health care professionals including independent practices, corporate retailers, hospitals and clinics or authorized resellers (collectively, its Customers). These Customers subsequently resell the Company’s products to eye care or health care providers and patients. In addition to product supply and distribution agreements with Customers, the Company enters into arrangements with health care providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks and discounts with respect to the purchase of the Company’s products. The Company considers customer purchase orders, which in some cases are governed by master sales agreements, to be contracts with a customer. In situations where sales are to a distributor, the Company has concluded that its contracts are with the distributor. As part of its consideration of the contract, the Company evaluates certain factors including the customer’s ability to pay (or credit risk). For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations. Revenues from product sales are recognized when the Customer obtains control of the Company’s product, which occurs at a point in time, typically upon shipment or delivery to the Customer. When the Company performs shipping and handling activities after the transfer of control to the Customer (e.g., when control transfers prior to delivery), they are considered as fulfillment activities, and accordingly, the costs are accrued for when the related revenue is recognized. Taxes collected from Customers relating to product sales and remitted to governmental authorities are excluded from revenues. The Company does not have any revenue recognized on payment expected to be received more than one year after the transfer of control of the products. The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that the Company would have recognized is one year or less. See Note14. Business Segment Information, for disaggregation of revenue. Reserves for Variable Consideration Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from discounts, returns, chargebacks, rebates and other allowances that are offered within contracts between the Company and its Customers, health care providers, payors and other indirect customers relating to the Company’s sales of its products. These reserves are based on the amounts earned or to be claimed on the related sales and are classified primarily in current liabilities. Variable consideration is estimated based on the most likely amount or expected value approach, depending on which method the Company expects to better predict the amount of consideration to which it will be entitled. Once the Company elects one of the methods to estimate variable consideration for a particular type of performance obligation, the Company applies that method consistently. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from the Company’s estimates, the Company adjusts these estimates, which would affect net product revenue and earnings in the period such variances become known. Trade Discounts and Allowances The Company generally provides Customers with discounts, which include incentive fees that are stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. In addition, the Company receives sales order management, data and distribution services from certain Customers. To the extent the services received are distinct from the Company’s sale of products to the Customer and have readily determinable fair value, these payments are classified in selling, general and administrative expenses in the Consolidated Statements of Income of the Company. Product Returns Consistent with industry practice, the Company generally offers Customers a limited right of return for a product that has been purchased from the Company. The Company estimates the amount of its product sales that may be returned by its Customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. There is inherent judgment in estimating future refunds as they are susceptible to factors outside of our influence. However, we have significant experience in estimating the amount of refunds, based primarily on historical data. Our refund liability for product returns was $9.9 million at July 31, 2019 which is included in Accrued Liabilities on our Condensed Consolidated Balance Sheets and represents the expected value of the aggregate refunds that will be due to our customers. Rebates and Chargebacks Rebates are estimated based on contractual terms, historical experience, customer mix, trend analysis and projected market conditions in the various markets served. Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list wholesale prices charged to the Company’s direct customers. For certain office and surgical products in CooperSurgical, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by Customers. CooperSurgical rebates are predominately related to the Medicaid rebate provision that is estimated based upon contractual terms, historical experience, and trend analysis. Contract balances The timing of billing and revenue recognition primarily occurs simultaneously. The Company does not have material contract assets or liabilities.

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Jul. 31, 2019
Business Combination And Asset Acquisition [Abstract]
Total purchase consideration for business and asset acquisitions	The following is a summary of the allocation of the total purchase consideration for business and asset acquisitions that the Company completed during fiscal 2019 and 2018: (In millions) July 31, 2019 October 31, 2018 Technology $ 12.3 $ — Customer relationships 7.5 23.5 Trademarks 10.2 100.0 Composite intangible asset — 1,061.9 Other 0.1 4.2 Total identifiable intangible assets $ 30.1 $ 1,189.6 Goodwill 35.8 70.6 Net tangible assets 1.3 59.6 Total purchase price $ 67.2 $ 1,319.8
Fair values of net assets acquired and liabilities assumed using the cost accumulation and allocation model for asset acquisition	The following table summarizes the relative fair values of net assets acquired and liabilities assumed using the cost accumulation and allocation model: (In millions) Relative Fair Value Composite intangible asset (1) $ 1,061.9 Assembled workforce intangible asset (2) 1.2 Property, plant and equipment 2.0 Inventory (3) 47.3 Other assets 9.4 Total assets acquired $ 1,121.8 Less: liabilities assumed 16.4 Total Purchase Price $ 1,105.4 The Company proportionally allocated the acquisition costs to the net assets acquired. The acquisition-related costs included advisory, legal, valuation and other professional fees. (1) Composite Intangible asset consists of technology, trade name, New Drug Application (NDA) approval and physician relationships, which have been valued as a single composite intangible asset as they are inextricably linked. The composite asset was identified as the primary asset acquired, was valued using the Multi-Period Excess Earnings Method and will be amortized over 15 years . (2) An assembled workforce was recognized as a separate acquired intangible asset, given the purchase of assets and will be amortized over 5 years . (3) Inventory relative fair value includes step up of $45.4 million .

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Jul. 31, 2019
Inventory Disclosure [Abstract]
Schedule of inventories	(In millions) July 31, 2019 October 31, 2018 Raw materials $ 127.1 $ 112.5 Work-in-process 13.4 12.6 Finished goods 361.6 343.7 $ 502.1 $ 468.8

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Jul. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of goodwill	Goodwill (In millions) CooperVision CooperSurgical Total Balance at October 31, 2017 $ 1,735.7 $ 619.1 $ 2,354.8 Net additions during the year ended October 31, 2018 36.8 34.4 71.2 Translation (29.6 ) (4.3 ) (33.9 ) Balance at October 31, 2018 1,742.9 649.2 2,392.1 Net additions during the nine months ended July 31, 2019 13.8 22.0 35.8 Translation (33.0 ) (3.5 ) (36.5 ) Balance at July 31, 2019 $ 1,723.7 $ 667.7 $ 2,391.4
Schedule of finite-lived intangible assets	Other Intangible Assets July 31, 2019 October 31, 2018 (In millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Weighted Average Amortization Period (In years) Intangible assets with definite lives: Trademarks $ 148.3 $ 24.6 $ 138.1 $ 16.9 14 Composite intangible asset 1,061.9 123.9 1,061.9 70.8 15 Technology 398.8 213.0 387.2 190.7 11 Customer relationships 356.1 187.0 350.0 168.6 13 License and distribution rights and other (1) 27.8 14.7 74.9 52.7 11 1,992.9 $ 563.2 2,012.1 $ 499.7 14 Less: accumulated amortization and translation 563.2 499.7 Intangible assets with definite lives, net 1,429.7 1,512.4 Intangible assets with indefinite lives, net (2) 8.9 8.9 Total other intangible assets, net $ 1,438.6 $ 1,521.3 (1) In the second quarter of fiscal 2019, CooperSurgical sold an exclusive distribution right to distribute Filshie Clip System in the U.S. for $21.0 million and recognized a gain of $19.0 million . In the third quarter of fiscal 2019, CooperVision removed $37.3 million of fully amortized non-compete agreements. (2)
Schedule of indefinite-lived intangible assets	Other Intangible Assets July 31, 2019 October 31, 2018 (In millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Weighted Average Amortization Period (In years) Intangible assets with definite lives: Trademarks $ 148.3 $ 24.6 $ 138.1 $ 16.9 14 Composite intangible asset 1,061.9 123.9 1,061.9 70.8 15 Technology 398.8 213.0 387.2 190.7 11 Customer relationships 356.1 187.0 350.0 168.6 13 License and distribution rights and other (1) 27.8 14.7 74.9 52.7 11 1,992.9 $ 563.2 2,012.1 $ 499.7 14 Less: accumulated amortization and translation 563.2 499.7 Intangible assets with definite lives, net 1,429.7 1,512.4 Intangible assets with indefinite lives, net (2) 8.9 8.9 Total other intangible assets, net $ 1,438.6 $ 1,521.3 (1) In the second quarter of fiscal 2019, CooperSurgical sold an exclusive distribution right to distribute Filshie Clip System in the U.S. for $21.0 million and recognized a gain of $19.0 million . In the third quarter of fiscal 2019, CooperVision removed $37.3 million of fully amortized non-compete agreements. (2)
Remaining amortization expenses for intangible assets with definite lives	As of July 31, 2019, the estimation of amortization expenses for intangible assets with definite lives is as follows: Fiscal years: (In millions) Remainder of 2019 $ 35.1 2020 135.6 2021 134.3 2022 132.4 2023 130.2 Thereafter 862.1 Total remaining amortization for intangible assets with definite lives $ 1,429.7

Debt (Tables)

Debt (Tables)	9 Months Ended
	Jul. 31, 2019
Debt Disclosure [Abstract]
Schedule of debt	(In millions) July 31, 2019 October 31, 2018 Overdraft and other credit facilities $ 65.0 $ 37.1 Term loans 325.0 — Short-term Debt $ 390.0 $ 37.1 Revolving credit $ — $ 439.0 Term loans 1,425.0 1,550.0 Other 0.2 0.2 Less: unamortized debt issuance cost (2.6 ) (3.5 ) Long-term Debt $ 1,422.6 $ 1,985.7 Total Debt $ 1,812.6 $ 2,022.8

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Jul. 31, 2019
Earnings Per Share [Abstract]
Schedule of earnings per share	Periods Ended July 31, Three Months Nine Months (In millions, except per share amounts) 2019 2018 2019 2018 Net income $ 120.1 $ 100.8 $ 345.7 $ 39.2 Basic: Weighted average common shares 49.5 49.1 49.4 49.0 Basic earnings per share $ 2.43 $ 2.05 $ 7.00 $ 0.80 Diluted: Weighted average common shares 49.5 49.1 49.4 49.0 Effect of potential dilutive shares 0.6 0.6 0.6 0.6 Diluted weighted average common shares 50.1 49.7 50.0 49.6 Diluted earnings per share attributable to Cooper stockholders $ 2.40 $ 2.03 $ 6.91 $ 0.79
Schedule of stock options and restricted stock units that were not included in the diluted earnings per share calculation	The following table sets forth stock options to purchase Cooper’s common stock and restricted stock units that were not included in the diluted earnings per share calculation because their effect would have been antidilutive for the periods presented: Periods Ended July 31, Three Months Nine Months (In thousands, except exercise prices) 2019 2018 2019 2018 Number of stock option shares excluded — 257 198 257 Range of exercise prices n/a $226.30-$230.09 $ 254.77 $226.30-$230.09 Numbers of restricted stock units excluded 18 78 19 78

Share-Based Compensation Plans

Share-Based Compensation Plans (Tables)	9 Months Ended
	Jul. 31, 2019
Share-based Payment Arrangement [Abstract]
Schedule of compensation expense and related income tax benefit for share-based awards	The compensation expense and related income tax benefit recognized in our Consolidated Condensed Statements of Income for share-based awards were as follows: Periods Ended July 31, Three Months Nine Months (In millions) 2019 2018 2019 2018 Selling, general and administrative expense $ 6.8 $ 6.7 $ 22.1 $ 30.3 Cost of sales 1.0 0.9 3.9 2.6 Research and development expense 0.5 0.5 2.4 1.6 Total share-based compensation expense $ 8.3 $ 8.1 $ 28.4 $ 34.5 Related income tax benefit $ 1.1 $ 1.5 $ 4.0 $ 7.1

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Jul. 31, 2019
Stockholders' Equity Note [Abstract]
Schedule of changes in accumulated other comprehensive (loss) income	Analysis of Changes in Accumulated Other Comprehensive (Loss) Income: (In millions) Foreign Currency Translation Adjustment Minimum Pension Liability Total Balance at October 31, 2017 $ (353.7 ) $ (21.6 ) $ (375.3 ) Gross change in value during the year ended October 31, 2018 (58.5 ) 11.0 (47.5 ) Tax effect for the period — (3.1 ) (3.1 ) ASU 2018-02 adoption (1) — (4.8 ) (4.8 ) Balance at October 31, 2018 $ (412.2 ) $ (18.5 ) $ (430.7 ) Gross change in value during the nine months ended July 31, 2019 (51.1 ) — (51.1 ) Balance at July 31, 2019 $ (463.3 ) $ (18.5 ) $ (481.8 ) (1) Represents reclassification to retained earnings from adoption of ASU 2018-02. Refer to our Annual Report on Form 10-K for the fiscal year ended October 31, 2018 for more details.

Employee Benefits (Tables)

Employee Benefits (Tables)	9 Months Ended
	Jul. 31, 2019
Retirement Benefits [Abstract]
Schedule of Components of Net Periodic Pension Costs	Our results of operations for the three and nine months ended July 31, 2019 and 2018 , reflect the following components of net periodic defined benefit costs: Periods Ended July 31, Three Months Nine Months (In millions) 2019 2018 2019 2018 Service cost $ 2.2 $ 2.7 $ 7.6 $ 8.1 Interest cost 2.1 1.3 4.6 3.8 Expected return on plan assets (2.8 ) (2.3 ) (7.4 ) (6.9 ) Recognized net actuarial loss (0.2 ) 0.4 0.6 1.2 Net periodic pension cost $ 1.3 $ 2.1 $ 5.4 $ 6.2

Business Segment Information (T

Business Segment Information (Tables)	9 Months Ended
	Jul. 31, 2019
Segment Reporting [Abstract]
Schedule of segment information	Segment information: Periods Ended July 31, Three Months Nine Months (In millions) 2019 2018 2019 2018 CooperVision net sales by category: Toric lens $ 163.1 $ 153.6 $ 464.4 $ 442.2 Multifocal lens 52.4 52.7 151.1 148.8 Single-use sphere lens 146.3 137.6 413.6 378.3 Non single-use sphere and other 147.3 145.2 434.2 432.1 Total CooperVision net sales 509.1 489.1 1,463.3 1,401.4 CooperSurgical net sales by category: Office and surgical products 106.3 104.4 307.7 290.4 Fertility 64.0 66.5 190.8 189.5 CooperSurgical net sales 170.3 170.9 498.5 479.9 Total net sales $ 679.4 $ 660.0 $ 1,961.8 $ 1,881.3 Operating income (loss): CooperVision $ 134.2 $ 125.4 $ 375.9 $ 361.1 CooperSurgical 20.6 1.6 59.0 (37.5 ) Corporate (12.6 ) (11.4 ) (34.8 ) (43.2 ) Total operating income 142.2 115.6 400.1 280.4 Interest expense 16.7 22.8 53.3 59.9 Other (income) expense, net (1.5 ) 2.4 (2.1 ) 1.3 Income before income taxes $ 127.0 $ 90.4 $ 348.9 $ 219.2
Schedule of identifiable assets by segment	(In millions) [to update] July 31, 2019 October 31, 2018 Total identifiable assets: CooperVision $ 3,801.3 $ 3,746.0 CooperSurgical 2,184.4 2,201.7 Corporate 187.1 165.1 Total $ 6,172.8 $ 6,112.8
Schedule of net sales to unaffiliated customers by country of domicile	Geographic information: Periods Ended July 31, Three Months Nine Months (In millions) 2019 2018 2019 2018 Net sales to unaffiliated customers by country of domicile: United States $ 306.2 $ 302.1 $ 891.1 $ 856.8 Europe 222.7 224.0 642.0 637.8 Rest of world 150.5 133.9 428.7 386.7 Total $ 679.4 $ 660.0 $ 1,961.8 $ 1,881.3
Schedule of net property, plant and equipment by country of domicile	(In millions) July 31, 2019 October 31, 2018 Net property, plant and equipment by country of domicile: United States $ 589.7 $ 516.7 Europe 339.7 340.7 Rest of world 136.0 118.6 Total $ 1,065.4 $ 976.0

General (Details)

General (Details) - Accounting Standards Update 2016-16 $ in Millions	Nov. 01, 2018USD ($)	[1]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect, decrease to retained earnings	$ 13.3
Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect, decrease to retained earnings	$ 13.3
[1]	We adopted ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory in the first quarter of fiscal 2019. Refer to “Note 1. General" for further information.

Revenue Recognition (Details)

Revenue Recognition (Details) $ in Millions	Jul. 31, 2019USD ($)
Capitalized Contract Cost [Line Items]
Refund liability for product returns	$ 9.9
Minimum
Capitalized Contract Cost [Line Items]
Capitalized contract cost, amortization period (or less)	1 year

Acquisitions - Total Purchase C

Acquisitions - Total Purchase Consideration for Business and Asset Acquisitions (Details) - USD ($) $ in Millions	Jul. 31, 2019	Oct. 31, 2018	Oct. 31, 2017
Schedule Of Business Acquisitions And Asset Acquisition, By Acquisition [Line Items]
Goodwill	$ 2,391.4	$ 2,392.1	$ 2,354.8
Technology
Schedule Of Business Acquisitions And Asset Acquisition, By Acquisition [Line Items]
Total identifiable intangible assets	12.3	0
Customer relationships
Schedule Of Business Acquisitions And Asset Acquisition, By Acquisition [Line Items]
Total identifiable intangible assets	7.5	23.5
Trademarks
Schedule Of Business Acquisitions And Asset Acquisition, By Acquisition [Line Items]
Total identifiable intangible assets	10.2	100
Composite intangible asset
Schedule Of Business Acquisitions And Asset Acquisition, By Acquisition [Line Items]
Total identifiable intangible assets	0	1,061.9
Other
Schedule Of Business Acquisitions And Asset Acquisition, By Acquisition [Line Items]
Total identifiable intangible assets	0.1	4.2
Acquisitions 2019
Schedule Of Business Acquisitions And Asset Acquisition, By Acquisition [Line Items]
Total identifiable intangible assets	30.1
Goodwill	35.8
Net tangible assets	1.3
Total purchase price	$ 67.2
Acquisitions 2018
Schedule Of Business Acquisitions And Asset Acquisition, By Acquisition [Line Items]
Total identifiable intangible assets		1,189.6
Goodwill		70.6
Net tangible assets		59.6
Total purchase price		$ 1,319.8

Acquisitions - Paragard (Detail

Acquisitions - Paragard (Details) - USD ($) $ in Millions	Nov. 01, 2017	Jul. 31, 2019
Schedule Of Asset Acquisition [Line Items]
Useful life		14 years
CooperSurgical | Paragard Intrauterine Device (IUD)
Schedule Of Asset Acquisition [Line Items]
Total purchase consideration	$ 1,100
Property, plant and equipment	2
Inventory	47.3
Other assets	9.4
Total assets acquired	1,121.8
Less: liabilities assumed	16.4
Total Purchase Price	1,105.4
Inventory step up	45.4
Composite intangible asset | CooperSurgical | Paragard Intrauterine Device (IUD)
Schedule Of Asset Acquisition [Line Items]
Intangible assets	$ 1,061.9
Useful life	15 years
Assembled workforce intangible asset | CooperSurgical | Paragard Intrauterine Device (IUD)
Schedule Of Asset Acquisition [Line Items]
Intangible assets	$ 1.2
Useful life	5 years

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Jul. 31, 2019	Oct. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 127.1	$ 112.5
Work-in-process	13.4	12.6
Finished goods	361.6	343.7
Inventories, net	$ 502.1	$ 468.8

Intangible Assets - Schedule of

Intangible Assets - Schedule of Goodwill (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Jul. 31, 2019	Oct. 31, 2018
Goodwill [Roll Forward]
Beginning balance	$ 2,392.1	$ 2,354.8
Net additions	35.8	71.2
Translation	(36.5)	(33.9)
Ending balance	2,391.4	2,392.1
CooperVision
Goodwill [Roll Forward]
Beginning balance	1,742.9	1,735.7
Net additions	13.8	36.8
Translation	(33)	(29.6)
Ending balance	1,723.7	1,742.9
CooperSurgical
Goodwill [Roll Forward]
Beginning balance	649.2	619.1
Net additions	22	34.4
Translation	(3.5)	(4.3)
Ending balance	$ 667.7	$ 649.2

Intangible Assets - Narrative (

Intangible Assets - Narrative (Details)	3 Months Ended
	Jul. 31, 2019USD ($)reporting_unit	Jul. 31, 2018USD ($)
Goodwill [Line Items]
Number of reporting units	3
Goodwill, Impairment Loss | $	$ 0	$ 0
CooperSurgical
Goodwill [Line Items]
Number of reporting units	2

Intangible Assets - Schedule _2

Intangible Assets - Schedule of Other Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Jul. 31, 2019	Apr. 30, 2019	Jul. 31, 2018	Jul. 31, 2019	Jul. 31, 2018	Oct. 31, 2018
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,992.9			$ 1,992.9		$ 2,012.1
Accumulated Amortization	563.2			563.2		499.7
Intangible assets with definite lives, net	1,429.7			$ 1,429.7		1,512.4
Weighted Average Amortization Period (In years)				14 years
Gain on sale of an intangible	0		$ 0	$ 19	$ 0
Amortization of intangibles	37.2		$ 37.7	110.7	$ 110.5
Intangible assets with indefinite lives, net	8.9			8.9		8.9
Total other intangible assets, net	1,438.6			1,438.6		1,521.3
Trademarks
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	148.3			148.3		138.1
Accumulated Amortization	24.6			$ 24.6		16.9
Weighted Average Amortization Period (In years)				14 years
Composite intangible asset
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,061.9			$ 1,061.9		1,061.9
Accumulated Amortization	123.9			$ 123.9		70.8
Weighted Average Amortization Period (In years)				15 years
Technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	398.8			$ 398.8		387.2
Accumulated Amortization	213			$ 213		190.7
Weighted Average Amortization Period (In years)				11 years
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	356.1			$ 356.1		350
Accumulated Amortization	187			$ 187		168.6
Weighted Average Amortization Period (In years)				13 years
License and distribution rights and other
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	27.8			$ 27.8		74.9
Accumulated Amortization	14.7			$ 14.7		$ 52.7
Weighted Average Amortization Period (In years)				11 years
CooperSurgical
Finite-Lived Intangible Assets [Line Items]
Proceeds from sale of exclusive distribution right to distribute Filshie Clip System in the U.S.		$ 21
Gain on sale of an intangible		$ 19
CooperVision | Noncompete Agreements
Finite-Lived Intangible Assets [Line Items]
Amortization of intangibles	$ 37.3

Intangible Assets - Remaining A

Intangible Assets - Remaining Amortization Expenses for Intangible Assets with Definite Lives (Details) - USD ($) $ in Millions	Jul. 31, 2019	Oct. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Remainder of 2019	$ 35.1
2020	135.6
2021	134.3
2022	132.4
2023	130.2
Thereafter	862.1
Intangible assets with definite lives, net	$ 1,429.7	$ 1,512.4

Debt - Schedule of Debt (Detail

Debt - Schedule of Debt (Details) - USD ($) $ in Millions	Jul. 31, 2019	Oct. 31, 2018
Short-term Debt
Short-term debt	$ 390	$ 37.1
Long-term Debt
Less: unamortized debt issuance cost	(2.6)	(3.5)
Long-term debt	1,422.6	1,985.7
Total Debt	1,812.6	2,022.8
Overdraft and other credit facilities
Short-term Debt
Short-term debt	65	37.1
Term loans
Short-term Debt
Short-term debt	325	0
Term loans
Long-term Debt
Long-term debt, gross	1,425	1,550
Other
Long-term Debt
Long-term debt, gross	0.2	0.2
Revolving Credit Facility | Line of Credit
Long-term Debt
Long-term debt, gross	$ 0	$ 439

Debt - Narrative (Details)

Debt - Narrative (Details) - USD ($)	Nov. 01, 2018	Nov. 01, 2017	Mar. 01, 2016	Jul. 31, 2019	Jul. 31, 2019	Oct. 31, 2018
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Short-term debt				$ 390,000,000	$ 390,000,000	$ 37,100,000
Term loans
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Short-term debt				325,000,000	325,000,000	0
Term loans
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt outstanding				1,425,000,000	1,425,000,000	1,550,000,000
Line of Credit | Revolving Credit Facility
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt outstanding				0	0	$ 439,000,000
Term Loan Agreement 2018 | Term loans
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, face amount	$ 400,000,000
Debt term	364 days
Short-term debt				$ 325,000,000	$ 325,000,000
Weighted average interest rate				3.02%	3.04%
Term Loan Agreement 2018 | Term loans | Base Rate
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate	0.00%
Term Loan Agreement 2018 | Term loans | London Interbank Offered Rate (LIBOR)
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate	0.60%
Term Loan Agreement 2017 | Term loans
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, face amount		$ 1,425,000,000
Debt term		5 years
Debt outstanding				$ 1,425,000,000	$ 1,425,000,000
Interest rate				3.36%	3.36%
Term Loan Agreement 2017 | Term loans | Base Rate | Minimum
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate		0.00%
Term Loan Agreement 2017 | Term loans | Base Rate | Maximum
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate		0.75%
Term Loan Agreement 2017 | Term loans | London Interbank Offered Rate (LIBOR) | Minimum
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate		1.00%
Term Loan Agreement 2017 | Term loans | London Interbank Offered Rate (LIBOR) | Maximum
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate		1.75%
Credit Agreement 2016 | Line of Credit | Revolving Credit Facility
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Aggregate principal amount			$ 1,000,000,000
Amount available under revolving credit facility				$ 998,800,000	$ 998,800,000
Credit Agreement 2016 | Line of Credit | Revolving Credit Facility | Minimum
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Commitment fee percentage			0.125%
Credit Agreement 2016 | Line of Credit | Revolving Credit Facility | Maximum
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Commitment fee percentage			0.25%
Credit Agreement 2016 | Line of Credit | Term Loan Facility 2016
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Aggregate principal amount			$ 830,000,000
Potential additional borrowing capacity			$ 750,000,000
Debt outstanding				$ 0	$ 0
Credit Agreement 2016 | Line of Credit | Revolving Credit Facility and Term Loan Facility 2016
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Required minimum interest coverage ratio					3
Required maximum total leverage ratio					3.75
Credit Agreement 2016 | Line of Credit | Revolving Credit Facility and Term Loan Facility 2016 | Base Rate | Minimum
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate			0.00%
Credit Agreement 2016 | Line of Credit | Revolving Credit Facility and Term Loan Facility 2016 | Base Rate | Maximum
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate			0.75%
Credit Agreement 2016 | Line of Credit | Revolving Credit Facility and Term Loan Facility 2016 | London Interbank Offered Rate (LIBOR) | Minimum
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate			1.00%
Credit Agreement 2016 | Line of Credit | Revolving Credit Facility and Term Loan Facility 2016 | London Interbank Offered Rate (LIBOR) | Maximum
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate			1.75%
Term Loan Agreement 2018 and 2017 and Credit Agreement 2016
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Interest coverage ratio				12.24	12.24
Total leverage ratio				1.83	1.83

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended		12 Months Ended
	Jul. 31, 2019	Jan. 31, 2019	Jul. 31, 2018	Jul. 31, 2019	Jul. 31, 2018	Oct. 31, 2018
Income Tax Disclosure [Abstract]
Income tax benefit to finalize tax effects of 2017 Act		$ 4.4
Effective income tax rate expense (benefit)	5.40%		(11.50%)	0.90%	82.10%
Provisional charge related to 2017 Act recorded in fiscal 2018						$ 196.7
Discrete tax benefits				$ 26.7
Unrecognized tax benefits	$ 50.7			50.7		$ 68.9
Unrecognized tax benefits that could be settled during the next twelve months	$ 8.1			$ 8.1

Earnings Per Share - Schedule o

Earnings Per Share - Schedule of Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended						9 Months Ended
	Jul. 31, 2019	Apr. 30, 2019	Jan. 31, 2019	Jul. 31, 2018	Apr. 30, 2018	Jan. 31, 2018	Jul. 31, 2019	Jul. 31, 2018
Earnings Per Share [Abstract]
Net income	$ 120.1	$ 122.4	$ 103.2	$ 100.8	$ 60.9	$ (122.5)	$ 345.7	$ 39.2
Basic:
Weighted average common shares (in shares)	49.5			49.1			49.4	49
Basic earnings per share (in dollars per share)	$ 2.43			$ 2.05			$ 7	$ 0.80
Diluted:
Effect of potential dilutive shares (in shares)	0.6			0.6			0.6	0.6
Diluted weighted average common shares (in shares)	50.1			49.7			50	49.6
Diluted earnings per share attributable to Cooper stockholders (in dollars per share)	$ 2.40			$ 2.03			$ 6.91	$ 0.79

Earnings Per Share - Schedule_2

Earnings Per Share - Schedule of Stock Options and Restricted Stock Units that were not Included in the Diluted Earnings Per Share Calculation (Details) - $ / shares shares in Thousands	3 Months Ended		9 Months Ended
	Jul. 31, 2019	Jul. 31, 2018	Jul. 31, 2019	Jul. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Range of exercise prices, lower limit		$ 226.3	$ 254.77	$ 226.3
Range of exercise prices, upper limit		$ 230.09	$ 254.77	$ 230.09
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of stock option shares and restricted stock units excluded (in shares)	0	257	198	257
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Number of stock option shares and restricted stock units excluded (in shares)	18	78	19	78

Share-Based Compensation Plan_2

Share-Based Compensation Plans - Schedule of Compensation Expense and Related Income Tax Benefit for Share-Based Awards (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jul. 31, 2019	Jul. 31, 2018	Jul. 31, 2019	Jul. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	$ 8.3	$ 8.1	$ 28.4	$ 34.5
Related income tax benefit	1.1	1.5	4	7.1
Selling, general and administrative expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	6.8	6.7	22.1	30.3
Cost of sales
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	1	0.9	3.9	2.6
Research and development expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total share-based compensation expense	$ 0.5	$ 0.5	$ 2.4	$ 1.6

Share-Based Compensation Plan_3

Share-Based Compensation Plans - Narrative (Details) - USD ($)	Mar. 18, 2019	Jul. 31, 2019	Oct. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Treasury stock (in shares)		3,600,000	3,600,000
Employee Stock Purchase Plan | Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee stock purchase plan, purchase price of common stock, percent of market price	85.00%
Employee stock purchase plan, maximum percentage of employee’s eligible compensation to purchase common stock	15.00%
Employee stock purchase plan, maximum amount of employee’s eligible compensation to purchase common stock	$ 21,300
Employee stock purchase plan, shares authorized (in shares)	1,000,000

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) Income (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Jul. 31, 2019	Oct. 31, 2018
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 3,307.8	$ 3,175.8
Gross change in value during the year ended October 31, 2018		(47.5)
Tax effect for the period		(3.1)
ASU 2016-16 adoption		(4.8)
Gross change in value during the nine months ended July 31, 2019	(51.1)
Ending balance	3,615.5	3,307.8
Foreign Currency Translation Adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(412.2)	(353.7)
Gross change in value during the year ended October 31, 2018		(58.5)
Tax effect for the period		0
ASU 2016-16 adoption		0
Gross change in value during the nine months ended July 31, 2019	(51.1)
Ending balance	(463.3)	(412.2)
Minimum Pension Liability
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(18.5)	(21.6)
Gross change in value during the year ended October 31, 2018		11
Tax effect for the period		(3.1)
ASU 2016-16 adoption		(4.8)
Gross change in value during the nine months ended July 31, 2019	0
Ending balance	(18.5)	(18.5)
Accumulated Other Comprehensive Income (Loss)
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(430.7)	(375.3)
Ending balance	$ (481.8)	$ (430.7)

Stockholders' Equity - Share Re

Stockholders' Equity - Share Repurchases (Details) - USD ($)	3 Months Ended			12 Months Ended
	Jul. 31, 2019	Apr. 30, 2019	Jan. 31, 2019	Oct. 31, 2018	Mar. 31, 2017	Dec. 31, 2011
Stockholders' Equity Note [Abstract]
Share repurchase program, authorized amount for repurchase					$ 1,000,000,000	$ 500,000,000
Share repurchase program, common stock repurchased (in shares)	0	0	24,500	0
Share repurchase program, common stock repurchased			$ 6,100,000
Share repurchase program, average purchase price (in dollars per share)			$ 248.70
Share repurchase program, remaining authorized amount for repurchase	$ 557,400,000

Stockholders' Equity - Dividend

Stockholders' Equity - Dividends (Details) - USD ($) $ / shares in Units, $ in Millions	Aug. 07, 2019	Feb. 08, 2019	Jul. 31, 2019	Jul. 31, 2018
Subsequent Event [Line Items]
Dividends on common stock		$ 1.5	$ 1.5	$ 1.5
Dividends on common stock (in dollars per share)		$ 0.03
Subsequent Event
Subsequent Event [Line Items]
Dividends on common stock	$ 1.5
Dividends on common stock (in dollars per share)	$ 0.03

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($)	Jul. 31, 2019	Oct. 31, 2018
Fair Value Disclosures [Abstract]
Derivative asset	$ 0	$ 0
Derivative liability	$ 0	$ 0

Employee Benefits - Schedule of

Employee Benefits - Schedule of Components of Net Periodic Defined Benefit Costs (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jul. 31, 2019	Jul. 31, 2018	Jul. 31, 2019	Jul. 31, 2018
Retirement Benefits [Abstract]
Service cost	$ 2.2	$ 2.7	$ 7.6	$ 8.1
Interest cost	2.1	1.3	4.6	3.8
Expected return on plan assets	(2.8)	(2.3)	(7.4)	(6.9)
Recognized net actuarial loss	(0.2)	0.4	0.6	1.2
Net periodic pension cost	$ 1.3	$ 2.1	$ 5.4	$ 6.2

Employee Benefits - Narrative (

Employee Benefits - Narrative (Details) - USD ($) $ in Millions	9 Months Ended
	Jul. 31, 2019	Jul. 31, 2018
Retirement Benefits [Abstract]
Defined benefit plan, contributions by employer	$ 5	$ 5
Expected rate of return on plan assets for determining net periodic pension cost	8.00%

Contingencies (Details)

Contingencies (Details) $ in Millions	1 Months Ended	4 Months Ended
	Jul. 31, 2018USD ($)	Jun. 30, 2015action
Commitments and Contingencies Disclosure [Abstract]
Number of putative class action complaints filed (over) | action		50
Coopervision Litigation
Loss Contingencies [Line Items]
Litigation settlement amount | $	$ 3

Business Segment Information -

Business Segment Information - Schedule of Segment Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jul. 31, 2019	Jul. 31, 2018	Jul. 31, 2019	Jul. 31, 2018
Segment Reporting Information [Line Items]
Total net sales	$ 679.4	$ 660	$ 1,961.8	$ 1,881.3
Total operating income	142.2	115.6	400.1	280.4
Interest expense	16.7	22.8	53.3	59.9
Other (income) expense, net	(1.5)	2.4	(2.1)	1.3
Income before income taxes	127	90.4	348.9	219.2
CooperVision
Segment Reporting Information [Line Items]
Total net sales	509.1	489.1	1,463.3	1,401.4
CooperSurgical
Segment Reporting Information [Line Items]
Total net sales	170.3	170.9	498.5	479.9
Toric lens | CooperVision
Segment Reporting Information [Line Items]
Total net sales	163.1	153.6	464.4	442.2
Multifocal lens | CooperVision
Segment Reporting Information [Line Items]
Total net sales	52.4	52.7	151.1	148.8
Single-use sphere lens | CooperVision
Segment Reporting Information [Line Items]
Total net sales	146.3	137.6	413.6	378.3
Non single-use sphere and other | CooperVision
Segment Reporting Information [Line Items]
Total net sales	147.3	145.2	434.2	432.1
Office and surgical products | CooperSurgical
Segment Reporting Information [Line Items]
Total net sales	106.3	104.4	307.7	290.4
Fertility | CooperSurgical
Segment Reporting Information [Line Items]
Total net sales	64	66.5	190.8	189.5
Operating Segments | CooperVision
Segment Reporting Information [Line Items]
Total operating income	134.2	125.4	375.9	361.1
Operating Segments | CooperSurgical
Segment Reporting Information [Line Items]
Total operating income	20.6	1.6	59	(37.5)
Corporate
Segment Reporting Information [Line Items]
Total operating income	$ (12.6)	$ (11.4)	$ (34.8)	$ (43.2)

Business Segment Information _2

Business Segment Information - Schedule of Identifiable Assets by Segment (Details) - USD ($) $ in Millions	Jul. 31, 2019	Oct. 31, 2018
Segment Reporting Information [Line Items]
Total Identifiable assets	$ 6,172.8	$ 6,112.8
Operating Segments | CooperVision
Segment Reporting Information [Line Items]
Total Identifiable assets	3,801.3	3,746
Operating Segments | CooperSurgical
Segment Reporting Information [Line Items]
Total Identifiable assets	2,184.4	2,201.7
Corporate
Segment Reporting Information [Line Items]
Total Identifiable assets	$ 187.1	$ 165.1

Business Segment Information _3

Business Segment Information - Schedule of Net Sales to Unaffiliated Customers by Country of Domicile (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Jul. 31, 2019	Jul. 31, 2018	Jul. 31, 2019	Jul. 31, 2018
Revenues from External Customers and Long-Lived Assets [Line Items]
Total net sales	$ 679.4	$ 660	$ 1,961.8	$ 1,881.3
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Total net sales	306.2	302.1	891.1	856.8
Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Total net sales	222.7	224	642	637.8
Rest of world
Revenues from External Customers and Long-Lived Assets [Line Items]
Total net sales	$ 150.5	$ 133.9	$ 428.7	$ 386.7

Business Segment Information _4

Business Segment Information - Schedule of Net Property, Plant and Equipment By Country of Domicile (Details) - USD ($) $ in Millions	Jul. 31, 2019	Oct. 31, 2018
Revenues from External Customers and Long-Lived Assets [Line Items]
Net property, plant and equipment	$ 1,065.4	$ 976
United States
Revenues from External Customers and Long-Lived Assets [Line Items]
Net property, plant and equipment	589.7	516.7
Europe
Revenues from External Customers and Long-Lived Assets [Line Items]
Net property, plant and equipment	339.7	340.7
Rest of world
Revenues from External Customers and Long-Lived Assets [Line Items]
Net property, plant and equipment	$ 136	$ 118.6

Uncategorized Items - coo201907

Label	Element	Value
Restricted Cash and Cash Equivalents, Current	us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue	$ 500,000
Restricted Cash and Cash Equivalents, Current	us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue	$ 0